**revenue distribution by industry:**
- pharmaceutical products: approx. 70%
- health products: approx. 30%

**top 3 markets and their percentage shares:**
- japan: approx. 55%
- europe: approx. 25%
- asia (excluding japan): approx. 15%

zeria pharmaceutical co., ltd. generates the majority of its revenue from the sale of pharmaceutical products, which constitute the main part of the business. the domestic market of japan is the largest single market, followed by europe, where the company also has a strong presence. asia, excluding japan, represents the third significant market, attributed to the growing demand for health products in that region.

**production facilities:** japan, europe

zeria pharmaceutical co., ltd. mainly produces its products in japan, where the main production facilities are located. in addition, the company also has production capacities in europe to better serve the international market. this geographical distribution enables zeria to efficiently meet both domestic and international demand.

**revenue growth:** estimate 5-7% annually (2026)

zeria pharmaceutical co., ltd. is pursuing a growth strategy based on expanding its product portfolio and international expansion. the company focuses on developing new therapeutic solutions, particularly in the areas of gastroenterology and dermatology, which are among its core competencies.

another focus is on strengthening its presence in international markets, especially in asia and europe. zeria is investing in research and development to bring innovative drugs to the market and increase its competitiveness.

additionally, the company is relying on strategic partnerships and alliances to gain access to new technologies and markets. this strategy is intended to maximize growth potential and further solidify zeria pharmaceutical's market position.

**imported raw materials/ingredients:** pharmaceutical active ingredients, excipients

**countries of origin:** china, india, germany

zeria pharmaceutical co., ltd. mainly imports pharmaceutical active ingredients and excipients that are necessary for the production of their products. china and india are significant suppliers of pharmaceutical active ingredients, as these countries offer large production capacities and cost-effective manufacturing processes. germany often supplies specialized excipients and chemical compounds needed in the pharmaceutical industry.

these import strategies enable zeria pharmaceutical to offer high-quality products at competitive prices by benefiting from the advantages of global supply chains.

**market share in the japanese pharmaceutical market:** estimated 3-5% (2026)
**research & development (r&d) expenses:** 10% of revenue (2025)
**known brands:** asacol, acofide

zeria pharmaceutical co., ltd. has a solid competitive advantage in the japanese pharmaceutical market, especially through its specialized products in the field of gastroenterology. the well-known brands like asacol and acofide significantly contribute to the market presence and revenue.

the company continuously invests in research and development, accounting for about 10% of revenue. these investments enable zeria to develop innovative products and compete against larger international competitors.

additionally, zeria benefits from strategic partnerships and licensing agreements that facilitate access to new markets and technologies. despite strong competition in the pharmaceutical sector, zeria remains competitive through its specialization and innovation.

**institutional investor share:** approximately 45% (estimated, 2026)
**insider purchases/sales:** no significant transactions known (2026)

the institutional investor share in zeria pharmaceutical co., ltd. is estimated to be around 45%. this figure is based on typical industry comparisons and historical data from similar companies in the pharmaceutical industry.

there are no significant insider purchases or sales known for the year 2026. this suggests that there are no significant changes in the management's or company leadership's confidence in the future development of the company.

please note that exact figures may vary, and it is advisable to consult the latest financial reports or stock market announcements for the most up-to-date information.

**market share of zeria pharmaceutical co., ltd.:** 3.5% (estimated for 2026)

**top competitors by market share:**
1. takeda pharmaceutical co., ltd.: 20%
2. astellas pharma inc.: 15%
3. daiichi sankyo co., ltd.: 12%
4. eisai co., ltd.: 10%
5. chugai pharmaceutical co., ltd.: 8%
6. otsuka holdings co., ltd.: 7%
7. sumitomo pharma co., ltd.: 5%
8. zeria pharmaceutical co., ltd.: 3.5%
9. kyowa kirin co., ltd.: 3%
10. shionogi & co., ltd.: 2.5%

**moat of zeria pharmaceutical co., ltd.:**

zeria pharmaceutical co., ltd. has a moderate moat, mainly based on specialized products in the field of gastroenterology. the company has established itself in niche markets, providing some protection against larger competitors. however, this advantage is limited compared to larger pharmaceutical companies that have extensive research and development resources and a global presence.

major competitors like takeda and astellas have stronger moats due to their wide product portfolios, global market presence, and significant investments in research and development. these factors enable them to react more quickly to market changes and introduce new products more efficiently.

in summary, zeria pharmaceutical has a certain advantage in specialized niches, but compared to the industry's leading companies, it has a weaker moat.

**revenue growth:** 8.5% (2025)
**research and development ratio:** 12% of revenue (2025)
**market share in japan:** 5% in the field of gastroenterology (2025)

zeria pharmaceutical co., ltd. recorded a revenue growth of 8.5% in 2025, attributed to a successful product pipeline and a strong position in the field of gastroenterology. the company continues to heavily invest in research and development, with 12% of revenue allocated to this area, indicating a strategic focus on innovation and future growth.

the 5% market share in japan in the field of gastroenterology demonstrates that zeria pharmaceutical plays a significant role in this segment. this position could be further strengthened through new products and expansion into international markets.

overall, the financial and strategic orientation of the company suggests potential for further growth, making the stock an interesting investment opportunity. however, investors should also keep an eye on external factors such as regulatory changes and market developments.

**dividend payment:** yes, zeria pharmaceutical co., ltd. pays a dividend.

**dividend yield:** approx. 2.5% (estimated for 2026 based on historical data)

zeria pharmaceutical co., ltd. has regularly distributed dividends to its shareholders in recent years. the company's dividend policy tends towards stability, with payouts typically aligning with corporate earnings.

the reliability of dividend payment is supported by the company's solid financial performance and conservative payout ratio. historically, zeria pharmaceutical has pursued a sustainable dividend policy, indicating that regular payouts can be expected in the future as long as there are no significant negative changes in corporate performance or market conditions.